Novel molecule shows promise against Covid variants: Study

The target proteins are also crucial for other viruses similar to SARS-CoV-2 such as MERS, SARS that are dangerous for humans.

February 18, 2023 03:30 pm | Updated 05:14 pm IST

Researchers have developed a novel molecule that has shown promise in lab tests as a potential preventive against the variants of the SARS-CoV-2 virus.

Researchers have developed a novel molecule that has shown promise in lab tests as a potential preventive against the variants of the SARS-CoV-2 virus. | Photo Credit: Getty Images/iStockphoto

Researchers have developed a novel molecule that has shown promise in lab tests as a potential preventive against the variants of the SARS-CoV-2 virus.

Developed by a team at Shiv Nadar Institution of Eminence Delhi-NCR and Paris Cité University in France, the compounds are based on indole which are ubiquitous molecules found in some amino acids and natural alkaloids.

"The current molecules are designed to treat the acute and long-term symptoms of COVID-19," said Subhabrata Sen, Professor at Department of Chemistry, Shiv Nadar Institution of Eminence.

"They are first in class molecules displaying the original property of targeting not only one but several molecular targets involved in COVID-19," Sen, corresponding author of the study published in the European Journal of Medicinal Chemistry, told PTI.

The scientist noted that due to its multi-target properties, the compounds interfere with several stages of SARS-CoV-2 infection, including interacting with its cellular receptor, ACE2 and viral replication.

These target proteins are also crucial for other viruses similar to SARS-CoV-2 such as MERS, SARS that are dangerous for humans, he noted.

"The therapeutic potential of our compounds for these viruses is currently unknown but would be of great interest to investigate," Sen said.

"Our compounds inhibit at least four COVID-19-related target proteins, however not with the same strength against all targets. Optimising and improving the efficacy of our molecules against all targets will be the next challenging step," he added.

However, there are many challenges before taking these compounds from the lab to the market.

"We need to optimise them, validate them in pre-clinical animal studies followed by meeting with Drugs Controller General of India (DCGI) to initiate clinical trials which will be time consuming," Sen said.

"Such studies will largely accelerate the application of our compounds to diseases associated with other SARS-CoV-2-related viruses," he added.

The good news, Sen said, is that the molecule has undergone in vivo (in living cells) studies against virulent SARS CoV-2 in Paris and no toxic limitations were recorded.

The researcher noted that there are only handful of novel molecules as SARS CoV-2 inhibitors around the world where the pathway of action has been elucidated and demonstrated.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.